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MTHFR C677T And pRoTHRoMbin G20210A MuTATions 
in A woMAn FRoM dAlMATiA wiTH silenT bRAin 
inFARCTion
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suMMARY – A 55-year-old, previously healthy woman, presented with frequent headaches. 
she had no neurological disturbances, but had a positive family history; her father died from stroke. 
Magnetic resonance imaging showed brain infarction; therefore detailed diagnostic evaluation of 
thrombophilia markers and genetic testing were performed. The patient was found to be homozy-
gous for the C677T mutation of the methylenetetrahydrofolate reductase gene and heterozygous for 
the mutation of the prothrombin G20210A gene. no other cause of cerebral infarction was found 
in the patient.
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Introduction
silent stroke, and in particular silent brain infarc-
tion (sbi), is a term widely used to describe cerebral 
infarcts seen on brain imaging without any, or with 
unrecognizable corresponding stroke episode. often, 
routine screening imaging is performed in healthy 
people as part of medical evaluation, resulting in sbis 
detected in people of all ages. sbi was usually defined 
as focal T2 hyperintensities >3 mm with correlative 
T1 hypointensities1. 
stroke is a multi-factorial polygenic, complex dis-
ease resulting from a combination of vascular, envi-
ronmental and genetic factors. Many meta-analyses 
demonstrated positive associations of ischemic stroke 
with methylenetetrahydrofolate reductase (MTHFR) 
C677T and prothrombin G20210A polymorphisms2,3. 
A patient with sbi associated with MTHFR 
C677T homozygous mutation and prothrombin 
G20210A heterozygous mutation is described.
Case Report
A 55-year-old woman was referred to the Clinical 
department of neurology, split university Hospital 
Center because of frequent headaches. she had dif-
fuse, persistent pain of mild to moderate intensity, 
vomiting and vertigo excluded. Headache occurred 
frequently and lasted for more than 24 hours. Tak-
ing analgesics decreased the pain, but not completely. 
Her family history was positive for vascular disorders, 
i.e. her father died from stroke. she had no other 
chronic disease and had not been taking drugs by that 
time. neurological examination showed no menin-
geal signs, no cranial nerve deficits, negative Rom-
berg’s sign, no difficulty in performing coordination 
tests, and no signs of ataxia or nystagmus. Routine 
laboratory tests were negative too. due to the family 
history and frequent headaches that had not resolved 
completely after taking analgesics, she was referred to 
undergo magnetic resonance imaging (MRi), which 
recorded vascular lesions (Figs. 1 and 2). After these 
findings, she was referred for diagnostic evaluation of 
thrombophilia markers. The patient was found to be 
homozygous for the C677T mutation of the methyl-
enetetrahydrofolate reductase (MTHFR) gene and 
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heterozygous for the mutation of the prothrombin 
G20210A gene by polymerase chain reaction (pCR) 
analysis. Genetic analysis of Factor V leiden, plas-
minogen activator inhibitor (pAi) and angiotensin 
converting enzyme (ACe) was normal. other throm-
bophilia markers including protein s, protein C and 
antithrombin iii proved normal. lupus anticoagulant 
tests and serum titers of anticardiolipin igG and igM, 
β2 glycoprotein 1 igG and igM, and antinuclear and 
anti-dnA antibodies were normal. Routine labora-
tory tests for the most common autoimmune diseases 
were also negative. in addition, serum cholesterol, 
triglycerides, high-density lipoprotein, low-density 
lipoprotein, and complement components C3 and 
C4 concentrations were normal. Homocysteine level 
was also normal (5.6 μmol/l). she was referred to the 
cardiologist as well. electrocardiogram, cardiac ul-
trasonography and cardiac examinations did not yield 
any pathologic findings and no other cause of cerebral 
infarction was found in the patient. The patient did 
not have any other risk factors such as obesity, smok-
ing, high blood pressure, diabetes, or using some hor-
mone therapy. 
she was treated with oral anticoagulants, moni-
toring coagulation parameters daily, and maintaining 
the inR index between 2 and 3. The anticoagulation 
regimen was administered over two months, and then 
it was substituted with aspirin (100 mg/day). Her diet 
was not poor in vitamins, but a multivitamin (folic 
acid and other b vitamins) was given with the anti-
platelet agent, notwithstanding the incompletely es-
tablished role of vitamins in preventing endothelial 
damage. on the last follow up, her neurological find-
ing was stable.
Discussion
in general population, the prevalence of sbi as de-
fined by MRi ranges from 8% to 28%, with a higher 
prevalence with increasing age1,4,5. Although silent 
infarcts, by definition, lack clinically overt stroke-like 
symptoms, they are associated with subtle deficits in 
physical and cognitive function that commonly go 
unnoticed. Moreover, the presence of silent infarcts 
more than doubles the risk of subsequent stroke and 
dementia. because of that, screening and treating 
Fig. 1. Magnetic resonance imaging (diffusion-weighted 
imaging, DWI).
Fig. 2. Magnetic resonance imaging (fluid attenuated in-
version recovery, FLAIR).
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high-risk patients can effectively reduce the risk of 
further infarcts, stroke and dementia1.
Headache is more common in strokes in the pos-
terior circulation and in cerebellar infarctions than in 
strokes in the anterior circulation, but then it occurs 
with dizziness, nausea, vomiting, and gait instability6. 
in our case, we show that vascular lesions can also go 
with nonspecific headache, but without other symp-
toms or neurologic disturbances. because of that, we 
classified these vascular lesions as sbi.
There are multiple genes involved in the patho-
genesis of stroke, e.g., factor V leiden Gln506, ACe 
i/d, MTHFR C677T, prothrombin G20210A, pAi-
1 5G allele and glycoprotein iiialeu33pro polymor-
phisms. Mutation of the prothrombin G20210A gene 
and especially mutation of the MTHFR C677T gene 
appear to be risk factors for stroke in adults, but also 
in children2,3. 
Among the risk factors for cerebral stroke, the 
MTHFR C677T mutation might lead to elevation 
of plasma concentration of homocysteine, which has 
been associated with an increased risk of ischemic 
stroke. Although the relationship between the in-
creased plasma homocysteine level and cardiovascular 
diseases is well-documented, the molecular mecha-
nism of endothelial damage has not yet been com-
pletely understood7-10. However, this mutation might 
exert its effect via a mechanism other than elevating 
homocysteine concentration, as in our case. Further 
studies are needed to verify how C677T mutation of 
the MTHFR gene can be a risk factor for stroke, re-
gardless of high homocysteine concentration.
prothrombin G20210A mutation was found to 
cause elevated levels of blood prothrombin (by one-
third above normal), which is more than the extra 
15% needed to develop thrombosis. Also, it has been 
proven that prothrombin G20210A mutation leads 
to increased mRnA and protein expression for pro-
thrombin11. in a sample of adult north Mediterra-
nean population younger than 65, the prevalence 
of prothrombin G20210A mutation was greater in 
patients with ischemic stroke than in matched con-
trols12. it is important to point out that the preva-
lence of prothrombin G20210A mutation is higher in 
south europe countries than in north europe coun-
tries, in spite of the overlapping between the north 
and south. The prevalence of prothrombin G20210 
mutation in general healthy population in Croatia is 
2.5%-4.0%13.
one of 7 patients with first-ever acute ischemic 
stroke will test positive for one of the inherited throm-
bophilias, but the relation is likely to be coincidental 
rather than causal in almost all cases, irrespective of 
the pathogenic subtype of ischemic stroke14. The situ-
ation is not different in Croatia. These results suggest 
that routine testing for thrombophilia in most pa-
tients with acute ischemic stroke may be unnecessary. 
whether thrombophilias may still be important in 
younger patients with ischemic stroke or in predict-
ing complications and stroke outcome, remains un-
certain. 
in conclusion, in middle-aged patients with find-
ings of brain vascular lesions on MRi, it is impor-
tant to examine the most common genetic mutations 
that are referred to as the risk of stroke, which include 
C677T mutation of the MTHFR gene and muta-
tion of the prothrombin G20210A gene, especially 
in patients with no other risk factors such as obesity, 
smoking, high blood pressure, diabetes, or using some 
hormone therapy. identification of these mutations is 
important in the overall assessment and management 
of patients at high risk. it is also important because 
of initiation of antithrombotic therapy for either pri-
mary or secondary thromboprophylaxis, duration of 
therapy, the potential of avoiding clinical thrombosis 
by risk factor modification, and genetic counseling of 
family members.
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MTHFR C677T i pRoTRoMbin G20210A MuTACiJe u bolesniCe iz dAlMACiJe s TiHiM 
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